[1] HUFFMAN M D,BHATNAGAR D.Novel treatments for cardiovascular disease prevention[J].Cardiovasc Ther,2012,30(5):257-263.
[2] YAMAGISHI S.Cardiovascular disease in recent onset diabetes mellitus[J].J Cardiol,2011,57(3):257-262.
[3] 胡大一,潘长玉.中国住院冠心病患者糖代谢异常研究[J].中华内分泌代谢杂志,2006,22(1):7-10.
[4] PRADEEPA R,MOHAN V.Postprandial glycemic excursions and cardiovascular risk[J].J Indian Med Assoc,2012,109(12):917-920.
[5] 关伟.糖尿病与冠心病急性心肌梗死[J].中国心血管杂志,2006,1(5):382-285.
[6] BARTNIK M,RYDÉN L,FERRARI R,et al.The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe:the Euro Heart Survey on Diabetes and the Heart[J].Eur Heart J,2004,25(21):1880-1890.
[7] SPRAFKA J M,BURKE G L,FOLSOM A R,et al.Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival.The Minnesota Heart Survey[J].Diabetes Care,1991,14(7):537-543.
[8] LEDRU F,DUCIMETIER E P,BATTAGLIA S,et al.New diagnostic criteria for diabetes and coronary artery disease:insights from an angiographic study[J].J Am Coll Cardiol,2001,37(6):1543-1550.
[9] McGILL Jr H C,McMAHAN C A,MALCOM G T,et al.Relation of glycohemoglobin and adiposity to atherosclerosis in youth.Pathobiological Determinants of Atherosclerosis in Youth(PDAY)Research Group[J].Arterioscler Thromb Vasc Biol,1995,15(4):431-440.
[10] JAFFE A S,SPADARO J J,SCHECHTMAN K,et al.Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus[J].Am Heart J,1984,108(1):31-37.
[11] KUUSISTO J,LAAKSO M.Prandial glucose regulation and cardiovascular disease in type 2 diabetes[J].Eur J Clin Invest,1999,29(Suppl)2:7-11.
[12] WEI M,GASKILL S P,HAFFNER S M,et al.Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality.The San Antonio Heart Study[J].Diabetes Care,1998,21(7):1167-1172.
[13] STANDL E,BALLETSHOFER B,DAHL B,et al.Predictors of 10-year macrovascular and overall mortality in patients with NIDDM:the Munich General.Practitioner Project[J].Diabetologia,1996,39(12):1540-1545.
[14] Emerging Risk Factors Collaboration.Diabetes mellitus,fasting blood glucose concentration,and risk of vascular disease:a collaborative meta-analysis of 102 prospective studies[J].Lancet,2010,375(9733):2215-2222.
[15] NEMET I,TURK Z,DUVNJAK L,et al.Humoral methylglyoxal level reflects glycemic fluctuation[J].Clin Biochem,2005,38(4):379-383.
[16] 周倩芸.糖化血红蛋白与冠心病的相关性研究[J].心血管病学进展,2008,29(4):619-621.
[17] KATSIKI N,PAPANAS N,MIKHAILIDIS D P,et al.Glycated hemoglobin A(1c)(HbA(1c))and diabetes:a new era？[J].Curr Med Res Opin,2011,27(SI3):7-11.
[18] 李黎,刘铁牛.糖化血红蛋白临床检测方法进展研究[J].国际检验医学杂志,2012,33(8):954-955.
[19] 刘慧,王蓓,张松,等.3 种检测系统测定糖化血红蛋白测量不确定度的评估[J].现代医学,2012,40(5):520-523.
[20] GOLDSTEIN D E,LITTLE R R,LORENZ R A,et al.Tests of glycemia in diabetes[J].Diabetes Care,2004,27(7):1761-1773.
[21] VASUDEVAN A R,BURNS A,FONSECA V A.The effectiveness of intensive glycemic control for the prevention of vascular complications in diabetes mellitus[J].Treat Endocrinol,2006,5(5):273-286.
[22] 林洁明,林大庆,江朝强,等.中老年人糖化血红蛋白水平与颈动脉内膜-中层厚度的相关性研究:广州生物库心血管疾病亚队列[J].中华糖尿病杂志,2010,2(3):170-174.
[23] KHAN H A,SOBKI S H,KHAN S A.Association between glycaemic control and serum lipids profile in type 2 diabetic patients:HbA1c predicts dyslipidaemia[J].Clin Exp Med,2007,7(1):24-29.
[24] RASOUL S,OTTERVANGER J P,BILO H J,et al.Glucose dysregulation in nondiabetic patients with ST-elevation myocardial infarction:acute and chronic glucose dysregulation in STEMI[J].Neth J Med,2007,65(3):95-100.
[25] CORPUS R A,O'NEILL W W,DIXON S R,et al.Relation of hemoglobin Alc to rate of major adverse Cardiac events in nondiabetic patients undergoing pereutaneous coronary revascularization[J].Am J Cardiol,2003,92(11):1282-1286.
[26] 王鹏,陈庆伟.HbA1c与冠状动脉病变程度的相关性研究[J].中国糖尿病杂志,2011,19(12):914-917.
[27] 陈汉阳,刘文娴,张丽洁.2型糖尿病合并冠心病患者冠脉病变与糖化血红蛋白水平的关系[J].中国介入心脏病学杂志,2011,19(2):88-90.
[28] 范泉,郭文怡,贾国良.冠心病患者糖化血红蛋白水平与冠状动脉病变的相关性[J].第四军医大学学报,2006,27(8):698-699.
[29] ADAMS R J,APPLETON S L,HILL C L,et al.Independent association of HbA(1c)and incident cardiovascular disease in people without diabetes[J].Obesity,2009,17(3):559-563.
[30] HADJADJ S,COISNE D,MAUCO G,et al.Prognostic value of admission plasma glucose and HbA1c in acute myocardial infarction[J].Diabetic Med,2004,21(4):305-310.
[31] TENERZ A,NILSSON G,FORBERG R.Basal glucometabolic status has an impact on long-term prognosis following an acute myocardial infarction in non-diabetic patients[J].J Intern Med,2003,254(5):494-503.
[32] RASOUL S,OTTERVANGER J P,BILO H J,et al.Glucose dysregulation in nondiabetic patients with ST-elevation myocardial infarction:acute and chronic glucose dysregulation in STEMI[J].Neth J Med,2007,65(3):95-100.
[33] SELVIN E,STEFFES M W,ZHU H,et al.Glycated hemoglobin,diabetes,and cardiovascular risk in nondiabetic adults[J].N Engl J Med,2010,362(9):800-811.
[34] SELVIN E,WATTANAKIT K,STEFFES M W,et al.HbA1c and peripheral arterial disease in diabetes:the Atherosclerosis Risk in Communities study[J].Diabetes Care,2006,29(4):877-882.
[35] UK Prospective Diabetes Study (UKPDS) Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type2 diabetes (UKPDS 33)[J].Lancet,1998,352(9131):837-853.
[36] TURNER R C,MILLNS H,NEIL H A,et al.Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus:United Kingdom Prospective Diabetes Study (UKPDS:23)[J].BMJ,1998,316(7134):823-828.
[37] EEG-OLOFSSON K,CEDERHOLM J,NILSSON P M,et al.New aspects of HbA1c as a risk factor for cardiovascular diseases in type2 diabetes:an observational study from the Swedish National Diabetes Register(NDR)[J].J Intern Med,2010,268(5):471-482.
[38] EEG-OLOFSSON K,CEDERHOLM J,NILSSON P M,et al.Glycemic control and cardiovascular disease in 7,454 patients with type1 diabetes:an observational study from the Swedish National Diabetes Register(NDR)[J].Diabetes Care,2010,33(7):1640-1646.
[39] BONDS D E,MILLER M E,BERGENSTAL R M,et al.The association between symptomatic,severe hypoglycaemia and mortality in type2 diabetes:retrospective epidemiological analysis of the ACCORD study[J].BMJ,2010,340:b4909.
[40] CALLES-ESCANDO'N J,LOVATO L C,SIMONS-MORTON D G,et al.Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics:the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial[J].Diabetes Care,2010,33(4):721-721.
[41] MILLER M E,BONDS D E,GERSTEIN H C,et al.The effects of baseline characteristics,glycaemia treatment approach,and glycated haemoglobin concentration on the risk of severe hypoglycaemia:post hoc epidemiological analysis of the ACCORD study[J].BMJ,2010,340:b5444.
[42] RIDDLE M C,AMBROSIUS W T,BRILLON D J,et al.Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial[J].Diabetes Care,2010,33(5):983-990.
[43] PARRY H,DONNELLY L,VAN Z,et al.Genetic variants predicting left ventricular hypertrophy in a diabetic population:a Go-DARTS study including meta-analysis.http://www.cardiab.com/content/12/1/109.2013-07-23/2013-07-25
[44] ADVANCE Collaborative Group,PATEL A,MacMAHON S,et al.Intensive blood glucose control and vascular outcomes in patients with type2 diabetes[J].N Engl J Med,2008,358(24):2560-2572. |
